433 related articles for article (PubMed ID: 34666765)
1. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
3. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
[No Abstract] [Full Text] [Related]
4. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Belhassen M; Dalon F; Nolin M; Van Ganse E
Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
6. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
Lee CT; Hao W; Burg CA; Best J; Kolenic GE; Strek ME
Respir Res; 2024 Jun; 25(1):255. PubMed ID: 38907239
[TBL] [Abstract][Full Text] [Related]
7. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.
Dempsey TM; Thao V; Moriarty JP; Borah BJ; Limper AH
BMC Pulm Med; 2022 Jan; 22(1):18. PubMed ID: 35000589
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
Dempsey TM; Sangaralingham LR; Yao X; Sanghavi D; Shah ND; Limper AH
Am J Respir Crit Care Med; 2019 Jul; 200(2):168-174. PubMed ID: 31150266
[No Abstract] [Full Text] [Related]
11. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
12. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study.
Romero Ortiz AD; Jiménez-Rodríguez BM; López-Ramírez C; López-Bauzá Á; Pérez-Morales M; Delgado-Torralbo JA; Villalba Moral C; Alcazar-Navarrete B
BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38663886
[TBL] [Abstract][Full Text] [Related]
13. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
[No Abstract] [Full Text] [Related]
15. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.
Kelly BT; Thao V; Dempsey TM; Sangaralingham LR; Payne SR; Teague TT; Moua T; Shah ND; Limper AH
BMC Pulm Med; 2021 Jul; 21(1):239. PubMed ID: 34273943
[TBL] [Abstract][Full Text] [Related]
16. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; de Andrade J
J Med Econ; 2022; 25(1):532-540. PubMed ID: 35321616
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Ntolios P; Archontogeorgis K; Anevlavis S; Bonelis K; Paxinou N; Voulgaris A; Froudarakis M; Steiropoulos P
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6326-6332. PubMed ID: 34730213
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
19. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
